| Date Filed | Type | Description |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/25/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/21/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/03/2023 |
SC 13G/A
| STATE STREET CORP reports a 0.3% stake in EXIT FILING CUE BIOPHARMA INC |
| 12/30/2022 |
424B7
| Form 424B7 - Prospectus [Rule 424(b)(7)]: |
| 12/15/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 12/15/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/06/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 12/02/2022 |
SC 13G/A
| Nantahala Capital Management, LLC reports a 0.3% stake in Cue Biopharma, Inc. |
| 11/21/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 11/18/2022 |
SC 13G
| Slate Path Capital LP reports a 5.6% stake in Cue Biopharma, Inc. |
| 11/15/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Form of Pre-Funded Warrant to Purchase Common Stock to be issued pursuant to the Securities Purchase Agreement",
"Form of Warrant to Purchase Common Stock or Pre-Funded Warrant to be issued pursuant to the Securities Purchase Agreement",
"Form of Securities Purchase Agreement, by and among the Company and the other parties thereto",
"Registration Rights Agreement, by and among the Company and the other parties thereto",
"Cue Biopharma Announces $30 Million Private Investment in Public Equity Financing BOSTON, Nov. 14, 2022 — Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it has entered into securities purchase agreements with certain accredited investors for a $30 million private investment in public equity financing. The PIPE financing included a life sciences-focused investment fund that is a new investor in the company as well as participation from other new and existing investors. Piper Sandler & Co. acted as lead placement agent and Public Ventures LLC acted as co-placement agent to Cue Biopharma for the PIPE financing. In..." |
|
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 06/22/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/30/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/16/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/16/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/18/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/14/2022 |
SC 13G/A
| Corriente Advisors, LLC reports a 0% stake in Cue Biopharma, Inc. |
| 02/14/2022 |
SC 13G/A
| Nantahala Capital Management, LLC reports a 8% stake in Cue Biopharma, Inc. |
| 02/10/2022 |
SC 13G
| STATE STREET CORP reports a 5.2% stake in INITIAL FILING CUE BIOPHARMA INC |
| 02/03/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/15/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/09/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
|